NLRP3 and inflammatory bowel disease: Compared with the expression observed in the IBD group, the BMSCs-Exo-treated group exhibited significantly reduced levels of NLRP3, Caspase-1, GSDMD, IL-1β and IL-18 (Figure 5A).